ASX / Media Release



11 June 2020

ACCC clears Ellex/Lumibird transaction

Adelaide, Australia, 11 June 2020 – Ellex Medical Lasers Limited (ASX:ELX; OTCQX: ELXMY, ELXMF), a world leader in medical technologies for the diagnosis and treatment of eye disease, today announces the outcome of the Australian Competition and Consumer Commission (ACCC) investigation, which focused on the impact on competition within the ophthalmology laser and ultrasound market in Australia if the proposed sale to Lumibird Group SA (Lumibird) was to proceed.

The ACCC has issued a public press release that it will not oppose the transaction. Feedback from customers and other industry participants suggested that this deal would not have a significant effect on competition. Moreover, the Australian market for these products was small compared to the markets the companies operate in globally, and that Lumibird has relatively low sales in each of the product categories in Australia.

Ellex and Lumibird have agreed to complete the transaction on 30 June 2020. To the extent there are conditions outstanding they are minor in nature and within control of the parties.

Ellex welcomes the ACCC decision and looks forward to completing the transaction and the associated returns to shareholders in the coming weeks ahead.

A revised timetable will be provided to the ASX in the upcoming days.

- ENDS -

This release dated 11 June 2020 has been authorised for lodgement to ASX by the Board of Directors of Ellex Medical Lasers Limited and lodged by Kimberley Menzies, Company Secretary.

ABOUT ELLEX

Ellex designs, develops, manufactures and sells innovative product that help eye surgeons around the world to effectively and efficiently treat eye disease. Ellex is a world leader in this field. Headquartered in Adelaide, Australia, Ellex has ophthalmic lasers and devices that treat glaucoma, retinal disease primarily caused by diabetes, secondary cataract and vitreous opacities, as well as age-related macular degeneration. Manufacturing is carried out in Adelaide, Australia and Fremont, California. Sales and service directly to eye surgeons is conducted via subsidiary offices in Minneapolis, Lyon, Berlin and Tokyo. A network of more than 50 distribution partners around the world services other markets.

For additional information about Ellex and its products, please visit www.ellex.com

For further information on Ellex please contact:

Victor Previn
Executive Chairman
Ellex Medical Lasers Limited
3 Second Avenue, Mawson Lakes SA 5095
W +61 8 7074 8200
vprevin@ellex.com

Dr. Tom Duthy
Investor Relations & Corporate Development
Ellex Medical Lasers Limited
3 Second Avenue, Mawson Lakes SA 5095
M +61 402 493 727
tduthy@ellex.com